Proteostasis Therapeutics Overview
- Founded
- 2006
- Status
- Acquired/Merged
- Employees
- 44
- Latest Deal Type
- M&A
Proteostasis Therapeutics General Information
Description
Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.
Contact Information
Primary Office
- 80 Guest Street
- 5th Floor
- Boston, MA 02135
- United States
Proteostasis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 22-Dec-2020 | 00000 | Completed | Generating Revenue/Not Profitable | ||
| 11. Secondary Transaction - Open Market | 00000 | Completed | Generating Revenue/Not Profitable | |||
| 10. Secondary Transaction - Open Market | 13-Apr-2017 | 00000 | Completed | Generating Revenue/Not Profitable | ||
| 9. PIPE | 08-Sep-2016 | 0000 | 00000 | Completed | Profitable | |
| 8. IPO | 11-Feb-2016 | 0000 | 00000 | 00000 | Completed | Profitable |
| 7. Later Stage VC (Series B) | 08-Sep-2015 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 6. Corporate | 09-Dec-2013 | 00000 | 00000 | Cancelled | Clinical Trials - Phase 1 | |
| 5. Grant | 05-Jun-2013 | 0000 | Completed | Clinical Trials - Phase 1 | ||
| 4. Early Stage VC (Series A) | 25-May-2011 | $20M | $89M | 000.00 | Completed | Startup |
| 3. Early Stage VC | 01-Dec-2010 | $23M | $69M | Completed | Startup |
Proteostasis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
Proteostasis Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discove
Drug Discovery
Boston, MA
44
As of 2019
00000
000000&0
00000
000000 0
lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000000000000
New York, NY
000
As of 0000
00000
0.00
0000-00-00
000000&0
00000
0000000
llamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vo
0000 000000000
San Diego, CA
00
As of 0000
00000
000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialProteostasis Therapeutics Competitors (68)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kadmon Holdings | Corporate Backed or Acquired | New York, NY | 000 | 00000 | 000000&0 | 00000 |
| 0000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
| 000000000 00000000 | Formerly VC-backed | Zurich, Switzerland | 000 | 00000 | 00000000 | 00000 |
| 00000000 | Formerly VC-backed | Paris, France | 00 | 000.00 | 000000000 | 000.00 |
Proteostasis Therapeutics Patents
Proteostasis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3814336-A1 | Proteasome activity enhancing compounds | Pending | 27-Jun-2018 | 0000000000 | |
| US-20210188802-A1 | Proteasome activity enhancing compounds | Pending | 27-Jun-2018 | 0000000000 | |
| US-20210115057-A1 | Proteasome activity enhancing compounds | Pending | 27-Jun-2018 | 0000000000 | |
| CA-3086674-A1 | Methods of quantifying cftr protein expression | Pending | 29-Dec-2017 | 0000000000 | |
| US-20200340984-A1 | Methods of quantifying cftr protein expression | Pending | 29-Dec-2017 | G01N33/543 |
Proteostasis Therapeutics Executive Team (24)
Proteostasis Therapeutics Board Members (17)
| Name | Representing | Role | Since |
|---|---|---|---|
| Meenu Chhabra | Proteostasis Therapeutics | President, Chief Executive Officer, Interim Principal Financial & Accounting Officer & Board Member | 000 0000 |
Proteostasis Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialProteostasis Therapeutics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Astellas Venture Management | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Biogen | Corporation | Minority | 000 0000 | 000000 0 | |
| Cormorant Asset Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Elan | Corporation | Minority | 000 0000 | 000000 0 | |
| F-Prime Capital | Venture Capital | Minority | 000 0000 | 000000 0 |
Proteostasis Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 22-Dec-2020 | 0000000 00 | Drug Discovery |